Wayne D Tilley

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8087618/wayne-d-tilley-publications-by-year.pdf
Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

176 papers	9,026 citations	56 h-index	88 g-index
194 ext. papers	10,554 ext. citations	7.9 avg, IF	5.69 L-index

#	Paper	IF	Citations
176	Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. *Nature Communications*, **2021**, 12, 6377	17.4	0
175	Jean Wilson and His Legacy, 50 Years and Counting. *Urology*, **2021**, 153, 1-5	1.6	
174	Androgen Receptor Signaling in Prostate Cancer Genomic Subtypes. *Cancers*, **2021**, 13,	6.6	4
173	High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids. *SLAS Discovery*, **2021**, 26, 1107-1124	3.4	1
172	Arming androgen receptors to oppose oncogenic estrogen receptor activity in breast cancer. *British Journal of Cancer*, **2021**, 125, 1599-1601	8.7	
171	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. *Nature Genetics*, **2021**, 53, 65-75	36.3	62
170	Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer. *Cell Reports*, **2021**, 34, 108585	10.6	10
169	The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. *Nature Medicine*, **2021**, 27, 310-320	50.5	40
168	A cell permeable bimane-constrained PCNA-interacting peptide. *RSC Chemical Biology*, **2021**, 2, 1499-1508		0
167	ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer. *Cancer Research*, **2021**, 81, 1704-1718	10.1	16
166	Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. *Cancer Research*, **2021**, 81, 4981-4993	10.1	8
165	An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. *Nature Cell Biology*, **2021**, 23, 1023-1034	23.4	8
164	Endonuclease FEN1 Coregulates ER Activity and Provides a Novel Drug Interface in Tamoxifen-Resistant Breast Cancer. *Cancer Research*, **2020**, 80, 1914-1926	10.1	10
163	Anti-proliferative transcriptional effects of medroxyprogesterone acetate in estrogen receptor positive breast cancer cells are predominantly mediated by the progesterone receptor. *Journal of Steroid Biochemistry and Molecular Biology*, **2020**, 199, 105548	5.1	5
162	Targeting CDK2 in cancer: challenges and opportunities for therapy. *Drug Discovery Today*, **2020**, 25, 406-413	8.8	58
161	Elevated levels of tumour apolipoprotein D independently predict poor outcome in breast cancer patients. *Histopathology*, **2020**, 76, 976-987	7.3	7
160	Heparanase Promotes Syndecan-1 Expression to Mediate Fibrillar Collagen and Mammographic Density in Human Breast Tissue Cultured. *Frontiers in Cell and Developmental Biology*, **2020**, 8, 599	5.7	6

159	MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer. *Breast Cancer Research*, **2020**, 22, 87	8.3	13
158	Androgen Receptor Signalling Promotes a Luminal Phenotype in Mammary Epithelial Cells. *Journal of Mammary Gland Biology and Neoplasia*, **2019**, 24, 99-108	2.4	3
157	Non-canonical AR activity facilitates endocrine resistance in breast cancer. *Endocrine-Related Cancer* , **2019**, 26, 251-264	5.7	15
156	Interplay between the androgen receptor signaling axis and microRNAs in prostate cancer. *Endocrine-Related Cancer*, **2019**, 26, R237-R257	5.7	11
155	Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update. *Journal of Medicinal Chemistry*, **2019**, 62, 4233-4251	8.3	87
154	A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer. *Oncogene*, **2019**, 38, 1136-1150	9.2	12
153	An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy. *International Journal of Cancer*, **2019**, 144, 1151-1159	7.5	11
152	The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome. *Clinical Cancer Research*, **2018**, 24, 2328-2341	12.9	32
151	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. *European Urology*, **2018**, 73, 715-723	10.2	71
150	New Opportunities for Targeting the Androgen Receptor in Prostate Cancer. *Cold Spring Harbor Perspectives in Medicine*, **2018**, 8,	5.4	17
149	Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. *European Urology*, **2018**, 74, 562-572	10.2	51
148	A patient-derived explant (PDE) model of hormone-dependent cancer. *Molecular Oncology*, **2018**, 12, 1608-1622	7.9	54
147	miR-200/375 control epithelial plasticity-associated alternative splicing by repressing the RNA-binding protein Quaking. *EMBO Journal*, **2018**, 37,	13	46
146	Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. *European Urology Oncology*, **2018**, 1, 325-337	6.7	23
145	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nature Genetics*, **2018**, 50, 928-936	36.3	340
144	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. *Nature Communications*, **2018**, 9, 2256	17.4	57
143	Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-and progesterone receptor-b. *British Journal of Cancer*, **2018**, 119, 1316-1325	8.7	6
142	Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer. *Cancer Research*, **2017**, 77, 3417-3430	10.1	49

141	Disrupting Androgen Receptor Signaling Induces Snail-Mediated Epithelial-Mesenchymal Plasticity in Prostate Cancer. *Cancer Research*, **2017**, 77, 3101-3112	10.1	43
140	MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. *Cancer Research*, **2017**, 77, 1021-1034	10.1	74
139	Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer. *Cancer Research*, **2017**, 77, 6282-6298	10.1	37
138	Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity. *Molecular and Cellular Endocrinology*, **2017**, 440, 138-150	4.4	75
137	Deciphering the divergent roles of progestogens in breast cancer. *Nature Reviews Cancer*, **2017**, 17, 54-64	31.3	73
136	Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. *Endocrine-Related Cancer*, **2016**, 23, T179-T197	5.7	100
135	IB mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor. *BMC Cancer*, **2016**, 16, 141	4.8	6
134	Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	27
133	Regulators of genetic risk of breast cancer identified by integrative network analysis. *Nature Genetics*, **2016**, 48, 12-21	36.3	100
132	Small Glutamine-Rich Tetratricopeptide Repeat-Containing Protein Alpha (SGTA) Ablation Limits Offspring Viability and Growth in Mice. *Scientific Reports*, **2016**, 6, 28950	4.9	7
131	Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. *Science Advances*, **2016**, 2, e1501924	14.3	69
130	Pushing estrogen receptor around in breast cancer. *Endocrine-Related Cancer*, **2016**, 23, T227-T241	5.7	26
129	Androgen and Estrogen Receptors in Breast Cancer Coregulate Human UDP-Glucuronosyltransferases 2B15 and 2B17. *Cancer Research*, **2016**, 76, 5881-5893	10.1	37
128	Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms. *Endocrine-Related Cancer*, **2015**, 22, 805-18	5.7	18
127	Progesterone receptor modulates ER action in breast cancer. *Nature*, **2015**, 523, 313-7	50.4	376
126	Expression and localisation of c-kit and KITL in the adult human ovary. *Journal of Ovarian Research*, **2015**, 8, 31	5.5	17
125	Hormone-sensing mammary epithelial progenitors: emerging identity and hormonal regulation. *Journal of Mammary Gland Biology and Neoplasia*, **2015**, 20, 75-91	2.4	10
124	Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. *Nucleic Acids Research*, **2015**, 43, 5880-97	20.1	121

123	Mouse GDF9 decreases KITL gene expression in human granulosa cells. *Endocrine*, **2015**, 48, 686-95	4	5
122	Expression of androgen receptor splice variants in clinical breast cancers. *Oncotarget*, **2015**, 6, 44728-44	3.3	56
121	Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues. *Hormones and Cancer*, **2014**, 5, 61-71	5	48
120	Epithelial plasticity in prostate cancer: principles and clinical perspectives. *Trends in Molecular Medicine*, **2014**, 20, 643-51	11.5	18
119	Human seminal fluid as a source of prostate cancer-specific microRNA biomarkers. *Endocrine-Related Cancer*, **2014**, 21, L17-21	5.7	29
118	Estrogen receptor beta in prostate cancer: friend or foe?. *Endocrine-Related Cancer*, **2014**, 21, T219-34	5.7	68
117	PRMT2 and RORexpression are associated with breast cancer survival outcomes. *Molecular Endocrinology*, **2014**, 28, 1166-85		36
116	Tailoring peptidomimetics for targeting protein-protein interactions. *Molecular Cancer Research*, **2014**, 12, 967-78	6.6	37
115	Bringing androgens up a NOTCH in breast cancer. *Endocrine-Related Cancer*, **2014**, 21, T183-202	5.7	21
114	Antiandrogenic actions of medroxyprogesterone acetate on epithelial cells within normal human breast tissues cultured ex vivo. *Menopause*, **2014**, 21, 79-88	2.5	13
113	Complexities of androgen receptor signalling in breast cancer. *Endocrine-Related Cancer*, **2014**, 21, T161-81	5.7	95
112	Breast cancer prognosis predicted by nuclear receptor-coregulator networks. *Molecular Oncology*, **2014**, 8, 998-1013	7.9	14
111	Acquired convergence of hormone signaling in breast cancer: ER and PR transition from functionally distinct in normal breast to predictors of metastatic disease. *Oncotarget*, **2014**, 5, 8651-64	3.3	20
110	Characterization of the prostate cancer susceptibility gene KLF6 in human and mouse prostate cancers. *Prostate*, **2013**, 73, 182-93	4.2	14
109	SGTA: a new player in the molecular co-chaperone game. *Hormones and Cancer*, **2013**, 4, 343-57	5	22
108	Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression. *Hormones and Cancer*, **2013**, 4, 154-64	5	16
107	Ski-interacting protein (SKIP) interacts with androgen receptor in the nucleus and modulates androgen-dependent transcription. *BMC Biochemistry*, **2013**, 14, 10	4.8	11
106	Knockdown of the cochaperone SGTA results in the suppression of androgen and PI3K/Akt signaling and inhibition of prostate cancer cell proliferation. *International Journal of Cancer*, **2013**, 133, 2812-23	7.5	13

105	Distinct nuclear receptor expression in stroma adjacent to breast tumors. *Breast Cancer Research and Treatment*, **2013**, 142, 211-23	4.4	36
104	Small glutamine-rich tetratricopeptide repeat-containing protein alpha is present in human ovaries but may not be differentially expressed in relation to polycystic ovary syndrome. *Fertility and Sterility*, **2013**, 99, 2076-83.e1	4.8	4
103	Hsp90: still a viable target in prostate cancer. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2013**, 1835, 211-8	11.2	23
102	Ex vivo culture of human prostate tissue and drug development. *Nature Reviews Urology*, **2013**, 10, 483-7	5.5	96
101	Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. *Nature Communications*, **2013**, 4, 1923	17.4	106
100	Identification of prostate cancer-associated microRNAs in circulation using a mouse model of disease. *Methods in Molecular Biology*, **2013**, 1024, 235-46	1.4	3
99	Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer. *Molecular Endocrinology*, **2013**, 27, 350-65		73
98	Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. *Oncotarget*, **2013**, 4, 691-704	3.3	43
97	Multiple nuclear receptor signaling pathways mediate the actions of synthetic progestins in target cells. *Molecular and Cellular Endocrinology*, **2012**, 357, 60-70	4.4	35
96	Dual roles of PARP-1 promote cancer growth and progression. *Cancer Discovery*, **2012**, 2, 1134-49	24.4	260
95	An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity. *Endocrine-Related Cancer*, **2012**, 19, 599-613	5.7	35
94	Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. *Cell Cycle*, **2012**, 11, 2756-61	4.7	171
93	Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. *Clinical Cancer Research*, **2012**, 18, 3562-70	12.9	85
92	Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. *International Journal of Cancer*, **2012**, 131, 652-61	7.5	139
91	A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. *International Journal of Cancer*, **2012**, 131, 662-72	7.5	28
90	Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. *EMBO Journal*, **2012**, 31, 1617-1617	13	1
89	Subdomain structure of the co-chaperone SGTA and activity of its androgen receptor client. *Journal of Molecular Endocrinology*, **2012**, 49, 57-68	4.5	19
88	Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor □n luminal breast cancer cells. *Molecular Endocrinology*, **2012**, 26, 1941-52		66

87	Circulating microRNAs: macro-utility as markers of prostate cancer?. *Endocrine-Related Cancer*, **2012**, 19, R99-R113	5.7	34
86	Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes. *Endocrine-Related Cancer*, **2012**, 19, 509-26	5.7	25
85	Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells. *Molecular and Cellular Endocrinology*, **2011**, 342, 20-31	4.4	12
84	Specific medical conditions associated with clinically significant depressive symptoms in men. *Social Psychiatry and Psychiatric Epidemiology*, **2011**, 46, 1303-12	4.5	23
83	Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. *EMBO Journal*, **2011**, 30, 3019-27	13	203
82	GSTP1 DNA methylation and expression status is indicative of 5-aza-2Rdeoxycytidine efficacy in human prostate cancer cells. *PLoS ONE*, **2011**, 6, e25634	3.7	41
81	Serum testosterone bioassay evaluation in a large male cohort. *Clinical Endocrinology*, **2010**, 72, 87-98	3.4	5
80	Breast and prostate cancer: more similar than different. *Nature Reviews Cancer*, **2010**, 10, 205-12	31.3	172
79	Androgen receptor levels during progression of prostate cancer in the transgenic adenocarcinoma of mouse prostate model. *Medical Journal of Indonesia*, **2010**, 5	0.4	2
78	Circulating steroid hormone levels and risk of breast cancer for postmenopausal women. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 492-502	4	83
77	A novel polymorphism in a forkhead box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3β,17β-diol glucuronide. *Molecular Pharmacology*, **2010**, 78, 714-22	4.3	29
76	Comparative biomarker expression and RNA integrity in biospecimens derived from radical retropubic and robot-assisted laparoscopic prostatectomies. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 1755-65	4	11
75	Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 2611-22	4	119
74	Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome. *Oncology Reports*, **2010**, 23, 1045-52	3.5	9
73	Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. *Cancer Research*, **2009**, 69, 6131-40	10.1	277
72	Finding the place of histone deacetylase inhibitors in prostate cancer therapy. *Expert Review of Clinical Pharmacology*, **2009**, 2, 619-30	3.8	4
71	A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin. *Endocrinology*, **2009**, 150, 2674-82	4.8	25
70	The dynamic and static modification of the epigenome by hormones: a role in the developmental origin of hormone related cancers. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2009**, 1795, 104-9	11.2	11

69	Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition. *Breast Cancer Research and Treatment*, **2009**, 115, 171-9	4.4	89
68	Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome. *Prostate*, **2009**, 69, 761-9	4.2	12
67	Insights from AR Gene Mutations **2009**, 207-240		1
66	Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors. *Journal of Steroid Biochemistry and Molecular Biology*, **2008**, 110, 236-43	5.1	57
65	The contribution of different androgen receptor domains to receptor dimerization and signaling. *Molecular Endocrinology*, **2008**, 22, 2373-82		103
64	Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse. *Cancer Epidemiology Biomarkers and Prevention*, **2008**, 17, 2488-97	4	23
63	Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential. *Prostate*, **2008**, 68, 830-8	4.2	41
62	Expression of Small Glutamine-Rich Tetratricopeptide Repeat-Containing Protein Alpha (SGT), a Novel Regulator of Androgen Receptor (AR) Activity, in the Human Ovary and Fallopian Tube.. *Biology of Reproduction*, **2008**, 78, 295-295	3.9	
61	Functional Androgen Signaling in an Explant Model of Normal Human Breast Tissue.. *Biology of Reproduction*, **2008**, 78, 142-142	3.9	
60	Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. *FASEB Journal*, **2007**, 21, 2285-93	0.9	71
59	Identification of novel androgen receptor target genes in prostate cancer. *Molecular Cancer*, **2007**, 6, 39	42.1	71
58	Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. *International Journal of Cancer*, **2007**, 120, 719-33	7.5	180
57	5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. *International Journal of Cancer*, **2007**, 120, 776-80	7.5	47
56	Changes in steroid receptors and proteoglycan expression in the guinea pig prostate stroma during puberty and hormone manipulation. *Prostate*, **2007**, 67, 288-300	4.2	9
55	Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. *Journal of Biological Chemistry*, **2007**, 282, 10814-25	5.4	116
54	Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2007**, 16, 763-8	4	84
53	Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha. *Cancer Research*, **2007**, 67, 10087-96	10.1	80
52	Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. *Molecular Cancer Therapeutics*, **2007**, 6, 51-60	6.1	88

51	Role of oncoprotein growth factor independent-1 (GFI1) in repression of 25-hydroxyvitamin D 1alpha-hydroxylase (CYP27B1): a comparative analysis in human prostate cancer and kidney cells. *Journal of Steroid Biochemistry and Molecular Biology*, **2007**, 103, 742-6	5.1	7
50	Uncoupling of hormone-dependence from chaperone-dependence in the L701H mutation of the androgen receptor. *Molecular and Cellular Endocrinology*, **2007**, 268, 67-74	4.4	9
49	Non-linear chromosomal inversion response in prostate after low dose X-radiation exposure. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2006**, 602, 65-73	3.3	38
48	The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. *International Journal of Cancer*, **2006**, 119, 944-54	7.5	62
47	Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant. *Molecular Endocrinology*, **2006**, 20, 1009-24		16
46	Circulating steroid hormones and the risk of prostate cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2006**, 15, 86-91	4	145
45	Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA. *Cancer Epidemiology Biomarkers and Prevention*, **2006**, 15, 1142-7	4	22
44	Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2006**, 15, 1137-41	4	56
43	Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. *Prostate*, **2005**, 63, 19-28	4.2	94
42	Androgen metabolic genes in prostate cancer predisposition and progression. *Frontiers in Bioscience - Landmark*, **2005**, 10, 2892-903	2.8	6
41	Mutation of the androgen receptor causes oncogenic transformation of the prostate. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 1151-6	11.5	154
40	GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor. *Biological Chemistry*, **2005**, 386, 69-74	4.5	24
39	Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. *Cancer Research*, **2005**, 65, 8487-96	10.1	55
38	Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. *Clinical Cancer Research*, **2004**, 10, 2491-8	12.9	120
37	Androgen receptor signaling: mechanism of interleukin-6 inhibition. *Cancer Research*, **2004**, 64, 2619-26	10.1	67
36	Structural and functional consequences of glutamine tract variation in the androgen receptor. *Human Molecular Genetics*, **2004**, 13, 1677-92	5.6	153
35	Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. *Endocrine-Related Cancer*, **2004**, 11, 459-76	5.7	192
34	Cancer-associated genes can affect somatic intrachromosomal recombination early in carcinogenesis. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2004**, 550, 1-10	3.3	10

33	Apolipoprotein-D: a novel cellular marker for HGPIN and prostate cancer. *Prostate*, **2004**, 58, 103-8	4.2	30
32	PC-3 cells with enhanced androgen receptor signaling: a model for clonal selection in prostate cancer. *Prostate*, **2004**, 60, 352-66	4.2	27
31	Dynamic methylation of histone H3 at lysine 4 in transcriptional regulation by the androgen receptor. *Nucleic Acids Research*, **2003**, 31, 6741-7	20.1	29
30	Expression of Drosophila Ca2+ permeable transient receptor potential-like channel protein in a prostate cancer cell line decreases cell survival. *Cancer Gene Therapy*, **2003**, 10, 611-25	5.4	9
29	ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer. *Journal of the National Cancer Institute*, **2003**, 95, 818-24	9.7	45
28	Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. *Molecular Cancer Research*, **2003**, 1, 385-92	6.6	43
27	Modulation of prostate cancer cell attachment to matrix by versican. *Cancer Research*, **2003**, 63, 4786-91	10.1	61
26	A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. *Molecular Endocrinology*, **2002**, 16, 2692-705		14
25	Contribution of the androgen receptor to prostate cancer predisposition and progression **2002**, 71-87		
24	Contribution of the androgen receptor to prostate cancer predisposition and progression. *Cancer and Metastasis Reviews*, **2001**, 20, 207-23	9.6	124
23	Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. *Molecular Endocrinology*, **2001**, 15, 46-56		92
22	Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. *Journal of Biological Chemistry*, **2001**, 276, 11204-13	5.4	97
21	Androgen receptor expression in primary prostate cancers of Lobund-Wistar rats and in tumor-derived cell lines. *In Vitro Cellular and Developmental Biology - Animal*, **1999**, 35, 655-62	2.6	5
20	Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells. *Molecular and Cellular Endocrinology*, **1999**, 154, 11-20	4.4	90
19	MOLECULAR DETECTION OF PROSTATE CELLS IN EJACULATE AND URETHRAL WASHINGS IN MEN WITH SUSPECTED PROSTATE CANCER. *Journal of Urology*, **1999**, 161, 1337-1343	2.5	23
18	Immunolocalization of apolipoprotein D, androgen receptor and prostate specific antigen in early stage prostate cancers. *Journal of Urology*, **1998**, 159, 548-54	2.5	21
17	Vascular Endothelial Growth Factor (VEGF) Expression in Prostate Cancer and Benign Prostatic Hyperplasia. *Journal of Urology*, **1997**, 157, 2323-2328	2.5	144
16	Evidence for a novel mechanism of androgen resistance in the human prostate cancer cell line, PC-3. *Steroids*, **1995**, 60, 180-6	2.8	41

15	Differential Expression of Apolipoprotein-D and Prostate Specific Antigen in Benign and Malignant Prostate Tissues. *Journal of Urology*, **1995**, 154, 622-628	2.5	28
14	Glycosaminoglycans of guinea pig prostate fibromuscular stroma: influence of estrogen and androgen on levels and location of chondroitin sulfate. *Prostate*, **1994**, 25, 320-32	4.2	12
13	Regulation of androgen receptor gene expression by steroids and retinoic acid in human breast-cancer cells. *International Journal of Cancer*, **1992**, 52, 778-84	7.5	42
12	Androgen resistance associated with a mutation of the androgen receptor at amino acid 772 (Arg----Cys) results from a combination of decreased messenger ribonucleic acid levels and impairment of receptor function. *Journal of Clinical Endocrinology and Metabolism*, **1991**, 73, 318-25	5.6	61
11	Definition of the human androgen receptor gene structure permits the identification of mutations that cause androgen resistance: premature termination of the receptor protein at amino acid residue 588 causes complete androgen resistance. *Molecular Endocrinology*, **1990**, 4, 1105-16		130
10	Antipeptide antibodies to two distinct regions of the androgen receptor localize the receptor protein to the nuclei of target cells in the rat and human prostate. *Endocrinology*, **1990**, 126, 2359-68	4.8	150
9	Recent studies of the androgen receptor: new insights into old questions. *Molecular and Cellular Endocrinology*, **1990**, 68, C7-10	4.4	18
8	Development and characterization of primary cultures of smooth muscle cells from the fibromuscular stroma of the guinea pig prostate. *In Vitro Cellular & Developmental Biology*, **1989**, 25, 1016-24		25
7	Effect of pubertal development on estrogen receptor levels and stromal morphology in the guinea pig prostate. *Prostate*, **1989**, 15, 195-210	4.2	20
6	Steroid hormone and epidermal growth factor receptors in meningiomas. *ANZ Journal of Surgery*, **1989**, 59, 881-8	1	16
5	Xenografted small cell undifferentiated cancer of prostate: possible common origin with prostatic adenocarcinoma. *Prostate*, **1987**, 11, 271-9	4.2	52
4	Specific binding of oestradiol to guinea-pig prostate cytosol and nuclear fractions. *The Journal of Steroid Biochemistry*, **1985**, 22, 705-11		6
3	Distribution of oestrogen and androgen receptors between the stroma and epithelium of the guinea-pig prostate. *The Journal of Steroid Biochemistry*, **1985**, 22, 713-9		22
2	Androgens and the androgen receptor (AR)378-391		
1	Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition		2